Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 39Busulfan 15Idarubicin 14Cyclophosphamide 13Mitoxantrone 12Filgrastim 12Etoposide 12fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 11Daunorubicin 9Methotrexate 8Cyclosporine 8Tacrolimus 7Whole-Body Irradiation 5Mycophenolic Acid 5Clofarabine 5Cladribine 5Biopsy 5Azacitidine 5Arsenic Trioxide 5Antilymphocyte Serum 5Radiotherapy 4Gemtuzumab 4Flow Cytometry 4Decitabine 4Cyclosporins 4venetoclax 3pegylated granulocyte colony-stimulating factor 3Topotecan 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Monocytic, Acute × Bromodeoxyuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡